AbbVie Inc. (NYSE:ABBV) updated its FY17 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $5.53-5.55 for the period, compared to the Thomson Reuters consensus estimate of $5.54. AbbVie also updated its FY18 guidance to $6.37-6.57 EPS.
A number of research analysts have commented on ABBV shares. BidaskClub upgraded AbbVie from a buy rating to a strong-buy rating in a research note on Saturday. Piper Jaffray Companies reissued a buy rating and set a $85.00 price objective on shares of AbbVie in a research report on Thursday, August 3rd. Barclays PLC reaffirmed a hold rating and issued a $68.00 price target on shares of AbbVie in a report on Thursday, September 28th. Evercore ISI reiterated an outperform rating and issued a $100.00 price objective (up from $95.00) on shares of AbbVie in a research note on Saturday, September 30th. Finally, Zacks Investment Research lowered AbbVie from a buy rating to a hold rating in a research report on Wednesday, November 1st. Eight investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $93.68.
Shares of AbbVie Inc. (ABBV) traded down $0.46 during trading hours on Friday, reaching $95.43. 6,170,100 shares of the company were exchanged, compared to its average volume of 6,254,326. The company has a market capitalization of $153,081.67, a PE ratio of 18.06, a price-to-earnings-growth ratio of 1.33 and a beta of 1.51. AbbVie Inc. has a fifty-two week low of $58.60 and a fifty-two week high of $98.26. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.25.
AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.02. The company had revenue of $7 billion for the quarter, compared to analysts’ expectations of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. AbbVie’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.21 earnings per share. sell-side analysts predict that AbbVie Inc. will post 5.55 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio is currently 62.29%.
In other news, insider Henry O. Gosebruch sold 18,300 shares of the stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the completion of the transaction, the insider now directly owns 81,287 shares of the company’s stock, valued at approximately $7,360,537.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $85.02, for a total transaction of $705,666.00. Following the transaction, the senior vice president now directly owns 93,099 shares of the company’s stock, valued at $7,915,276.98. The disclosure for this sale can be found here. Insiders sold a total of 33,299 shares of company stock worth $2,952,243 in the last 90 days. 0.23% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/11/11/abbvie-inc-abbv-updates-fy17-earnings-guidance.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of ABBV. Los Angeles Capital Management & Equity Research Inc. grew its holdings in shares of AbbVie by 24.5% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 740,392 shares of the company’s stock valued at $53,686,000 after purchasing an additional 145,691 shares during the last quarter. Spectrum Management Group Inc. grew its holdings in shares of AbbVie by 11.5% during the 2nd quarter. Spectrum Management Group Inc. now owns 28,100 shares of the company’s stock valued at $2,038,000 after purchasing an additional 2,892 shares during the last quarter. AGF Investments America Inc. grew its holdings in AbbVie by 3.6% in the 2nd quarter. AGF Investments America Inc. now owns 29,064 shares of the company’s stock worth $2,107,000 after acquiring an additional 1,017 shares during the last quarter. Ffcm LLC grew its holdings in AbbVie by 167.2% in the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after acquiring an additional 963 shares during the last quarter. Finally, Fiduciary Trust Co. grew its holdings in AbbVie by 3.2% in the 2nd quarter. Fiduciary Trust Co. now owns 321,953 shares of the company’s stock worth $23,345,000 after acquiring an additional 10,113 shares during the last quarter. Institutional investors and hedge funds own 68.52% of the company’s stock.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.